Skip to main content

Table 3 Treatment comparisons for 10 min post challenge mean TNSS and mean nasal PIF over the last three days of the allergen challenge series.

From: Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis

Variable Treatment Mean differencea 95% CI P-value
TNSS AZD3778 vs. placebo -1.56 -2.03, -1.09 <0.001
  Loratadine vs. placebo -1.87 -2.34, -1.4 <0.001
  AZD3778 vs. loratadine 0.312 -0.149, 0.773 0.181
Nasal
PIF
AZD3778 vs. placebo 16.8 5.73, 27.9 0.004
  Loratadine vs. placebo 8.67 -2.43, 19.8 0.124
  AZD3778 vs. loratadine 8.14 -2.83, 19.1 0.143
  1. aAdjusted mean difference from ANOVA.
  2. AZD3778 as well as loratadine reduced post challenge TNSS. In addition, AZD3778 improved post challenge nasal PIF.